At Skanda Life Sciences, we provide comprehensive pre-clinical services for renal and hepatic disorders research.
Renal / Hepatic Disorders
At Skanda Life Sciences, we provide comprehensive pre-clinical services for renal and hepatic disorders research. Our renal tubular epithelial cell cultures and in vitro assays enable precise evaluation of drug-induced nephrotoxicity and renal disease mechanisms. Additionally, our hepatocyte cultures facilitate the study of drug metabolism, toxicity, and lipid metabolism in the liver. With a commitment to scientific excellence and innovation, we strive to address the unmet needs of patients with renal and hepatic disorders.
SKANDA offers specialized in vitro research services tailored to elucidate the intricacies of these conditions and facilitate drug discovery research. Our suite of in vitro screening assays encompasses a diverse array of methodologies to assess cellular responses and disease mechanisms associated with renal and hepatic disorders. These include:
Cytotoxicity and Viability Assays
Utilizing assays such as MTT, MTS, XTT, SRB to evaluate cell viability and cytotoxic effects of test compounds on renal and hepatic cells.
Biomarker Analysis
Measurement of relevant biomarkers associated with renal and hepatic function and pathology using ELISA or immunofluorescence assays.
Drug Metabolism and Hepatotoxicity or renal toxicity Assays
Employing hepatic cell models to investigate drug metabolism, bioactivation, and hepatotoxicity through enzyme activity assays and toxicity screening platforms.
Transporter Studies
Assessing the role of renal and hepatic transporters in drug disposition and toxicity using transporter inhibition assays and uptake transporter activity assays.
Inflammation and Fibrosis Assays
Modelling renal and hepatic inflammation and fibrosis processes using cell-based assays to study cytokine release, fibrogenesis, response to oxidative stress and other metabolic disorders.
